Sign in
Taking peoplePhase 3

Lessening Organ Dysfunction with VITamin C in septic ARDS

Key facts

Who runs it
Assistance Publique Hopitaux De Paris
Where
France17 sites in 1 countryChoose a country to see its sites
Status
Recruiting
Phase
Phase 3
People taking part
814 people, planned
Started
5 Nov 2024
Expected to end
6 Jul 2029
Type of study
Interventional
Record updated
22 June 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Patients ≥ 18 years old
  • Admitted to the ICU with proven or suspected infection as the main diagnosis
  • Currently treated with a continuous intravenous infusion of vasopressors (norepinephrine, epinephrine, vasopressin, dopamine, phenylephrine, angiotensin, others))
  • Currently treated with high flow oxygen, CPAP OR NIV OR Invasive Ventilation
  • Presenting with Acute Respiratory Distress Syndromedefined by all the following criteria: o Acute onset, i.e. within one week of an apparent clinical insult and with progression of respiratory syndrome o Bilateral opacities on chest imaging not explained by other pulmonary pathologies (e.g. pleural effusion, atelectasis, nodules, etc.) o No evidence for heart failure or volume overload o PaO2/FiO2 ≤ 200 mm Hg o PEEP ≥ 5 cm H2O
  • Patient who has signed an informed and written consent whenener he/she is capable of consent, if not, Patient’s representant signed consent whenever he/she is present at inclusion
  • Affiliation to a social security system or to an universal health coverage (Couverture Maladie Universelle, CMU)
  • Patients under guardianship or curatorship can be included
  • Patients in case of simple emergency (legal definition) or vital emergency will be included

Who cannot take part

  • Received any intravenous vitamin C during this hospitalization unless incorporated in parenteral nutrition (PN) in doses standard for PN
  • Previously enrolled in this study
  • Previously enrolled in an interventional trial for which co-enrolment is not allowed (co-enrolment to be determined case by case)
  • Treatment with Deferoxamine
  • Patient with critical COVID-19 according WHO definition
  • Known allergy excipients of vitamin C solution; or to one of the excipients in particular methyl parhydroxybenzoate (E218) or propyl (E216)
  • Known Glucose-6-phosphate dehydrogenase (G6PD) deficiency
  • 48 hours from diagnosis of ARDS
  • Expected death or withdrawal of life-sustaining treatments within 48 hours
  • Cardio-pulmonary resuscitation (CPR) in the past 72 hours
  • Pregnancy and breast-feeding
  • Hyperoxaluria
  • Known kidney stones within the past 1 year

This trial is currently available in France.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To compare the effect of high-dose intravenous vitamin C vs. placebo on a composite of death or persistent organ dysfunction – defined as continued dependency on mechanical ventilation, new renal replacement therapy, or vasopressors – assessed at 28 days on ICU patients

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
LOVIT-ARDS - A Multicentre Concealed‐Allocation Parallel‐Group Blinded Randomized Controlled Trial to Ascertain the Effect of High‐Dose Intravenous Vitamin C Compared to Placebo on Mortality or Persistent Organ Dysfunction at 28 Days in Septic ARDS Patients
Record updated
22 June 2026